Middle East respiratory syndrome coronavirus (MERS-CoV) is a newly recognized transmissible viral infection with high virulence and case fatality rates for which there is no currently defined primary treatment or prophylaxis. Saudi Arabia has the largest reported number of cases so far. Like severe acute respiratory syndrome (SARS), MERS is caused by a coronavirus. Combination therapy with interferon-α2b and ribavirin has been used successfully as primary treatment and prophylaxis in SARS. Because of similarities between the two coronaviruses, treatment with ribavarin and interferon-α2b has been suggested as a potential therapy for MERS-CoV. Studies in animal models of MERS-CoV have shown the combination of ribavirin and interferon-α2b to be effective both as primary treatment and prophylaxis. In this report, we describe for the first time use of this combination as a primary treatment for a patient with MERS-CoV infection and as prophylaxis for his spouse and discuss its possible role.
References
1.
ChanP.K., ChanM.C.Tracing the SARS coronavirus.J Thorac Dis2013; 5Suppl 2: S118–S121.
2.
de GrootR.J., BakerS.C., BaricR.S.Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group.J Virol2013; 87: 7790–7792.
3.
ZakiA.M., van BoheemenS., BestebroerT.M., OsterhausA.D., FouchierR.A.Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia.N Engl J Med2012; 367: 1814–1820.
GueryB., van der WerfS.Coronavirus: need for a therapeutic approach.Lancet Infect Dis2013; 13: 726–727.
6.
FalzaranoD., de WitE., RasmussenA.L.Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques.Nat Med2013; 19: 1313–1317.
7.
FalzaranoD., de WitE., MartellaroC.Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin.Sci Rep2013; 3: 1686.
8.
AssiriA., Al-TawfqJ.A., Al-RabeeahA.A.Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study.Lancet Infect Dis2013; 13: 752–761.
AssiriA., McGeerA., PerlT.M.Hospital outbreak of Middle East respiratory syndrome coronavirus.N Engl J Med2013; 369: 407–416.
11.
GautretP., BenkouitenS., SalaheddineI., ParolaP., BrouquiP.Preventive measures against MERS-CoV for Hajj pilgrims.Lancet Infect Dis2013; 13: 829–831.
12.
Al-TawfqJ.A., MomattinH., DipJ., MemishZ.A.Ribavirin and interferon in patients infected with the Middle East respiratory syndrome corona virus: an observational study.Int J Infect Dis2014; 20: 42–46.
13.
MomattinH., MohammedK., ZumiaA., MemishZ.A., Al-TawfqJ.A.Therapeutic options for Middle East respiratory syndrome coronavirus (MERS-CoV) – possible lessons from a systematic review of SARS-CoV therapy.Int J Infect Dis2013; 17: e792–e798.
